Financial Advice With Zero Return Many people rely on

New Post Public Reply Private Reply Replies (0) Message Board
NITE


Financial Advice With Zero Return
Many people rely on financial advisors, either independent ones or those employed at banks. The good ones will at least ensure that you have a sensibly diversified portfolio and that it stays that way. However, a recent study indicates that many advisors do not increase the actual investment returns on an ongoing basis.

What Advisors Do and Don't
An investigation conducted at the University of Frankfurt in Germany reveals that neither portfolios advised by banks nor independent advisors, do any better than those for which no advice was given. Finance professor Andreas Hackethal explains that the main problem is the failure of advisors "to correct systematic investment errors sufficiently, while at the same time, they generate additional costs." (For related reading, see Diversifying Your Portfolio.)

Furthermore, this work almost certainly applies to the United States. According to Hackethal, an investigation by Bergstresser et. al in the U.S., demonstrated that mutual funds sold through U.S. broker channels underperform other mutual funds. They take this as indirect evidence that brokers or advisors do not add value for clients.



The Frankfurt-based study used client data from a large German bank and from an online broker that specializes in providing independent advice. The survey sample that was given advice, performed no better than the execution-only group.

The researchers also confirm that banks (and certain other advisors) have the wrong incentive structures, so that the advisory process all too often helps only the seller and not the investor. (To learn more, read Paying Your Investment Advisor - Fees Or Commissions?)

Investor Reluctance to Obtain and Follow Good Advice
Good advisors are clearly hard to find, but they are indeed out there. However, Hackethal found a widespread client reluctance to use good, skilled advice, "preferring to rely on their own generally mediocre investment skills." A staggering 95% of those questioned were not even interested in free independent advice from an advisor with no incentive, at all, to recommend specific products.

Equally amazing is the fact that of the remaining 5%, only half actually followed the advice that they were given. Of this tiny group, half again followed the advice only half-heartedly, even though the recommendations would have led to substantially better returns.

It seems to be mainly wealthy, experienced investors who really appreciate the value of good advice from the right people. Yet, almost anyone would benefit from a second, objective opinion on what to do with their hard-earned savings.

The Solutions
The Frankfurt researchers do not believe that more governmental regulation is the answer either. In particular, given the above consumer attitudes to advice, purely seller-side regulation seems doomed to fail. For instance, Hackethal doubts that simply providing more information in the form of brochures, for example, will help much. It will take a lot more "to achieve the necessary transparency and learning effects … with respect to investment risks and opportunities."

Clearly, somehow, investor attitudes towards advice need to change and the incentive structures in the industry as well. In addition, investment selling processes at banks may need to be overhauled in a more general sense. There is a compelling need to establish just why, in so many instances, the advisory process fails to work for the investor.

There are undoubtedly independent and bank advisors who can and will help people get more "bang (and bank) for their buck." What is lacking is an understanding of the difference between good, mediocre and really bad advice. Above all, far greater market transparency is essential, so that people are able to draw the appropriate distinctions between a fine investment, a rip-off and the various shades of gray between the two extremes. At present, too many investors just do not know who they are dealing with. As Hackethal puts it "the person sitting opposite them could be excellent or an outright crook. The clients just don't know." (Learn more on how to Find The Right Financial Advisor.)

An Important Benefit Remains - with Genuinely Independent Advisors
Independent financial advice can, however, at least prevent excessively risky, undiversified portfolios. That is, even if an advisor does not lead to better returns, if they can prevent you from having a high risk portfolio that rockets in a boom and plummets in a bear market, that can be worth a lot. This is a separate issue and needs to be kept in mind. The above research dealt with better investment performance, not with avoiding disastrous losses in a crash.

The Bottom Line
Financial advice can be pretty ineffectual for two main reasons. Firstly, when the incentive structures are wrong, the advice benefits mainly or only the bank or broker. Secondly, investors are remarkably reluctant either to seek out or follow objective advice from a third party. Overcoming this highly unsatisfactory situation entails a combination of changed structures and attitudes on both the buyer and seller sides of the market. This is not easy to achieve, and regulation alone will certainly not do it. The industry needs to take a long, hard look at what it is doing, both wrong and right.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 47

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
Rising Medical Lands Ninth Spot on Inc. 5000

Updated Category News Views 144

Rising Medical's Continued Ascent In a world where the list of high-performing companies is as long as a trader's bad day, Rising Medical Solutions, out of Chicago, has snagged its ninth appearance on the Inc. 5000 list. This isn’t just any roll call; we're talking about a spotlight for America’s fastest-growing private companies—a badge of honor for business...

Continue Reading
Elanco Heads to UBS Global Healthcare—What Matters

Updated Category News Views 48

Elanco's Strategy Under the Spotlight at UBS Confab Right off the bat, let's chew over why Elanco’s trip to the UBS Global Healthcare Conference ain’t just another checkbox on a corporate to-do list. It’s where the nitty-gritty of their strategy reveals itself, as Bob VanHimbergen and Bobby Modi step into the spotlight on November 9. While not everyone's shouting...

Continue Reading
NJ Small Businesses: Free IT Security Checks Offered

Updated Category News Views 116

Unpacking Corporate Technologies' Offer It's not every day a company doles out free consultations, but Corporate Technologies is doing just that. They're tossing New Jersey's small-to-mid businesses a lifeline with free IT and cybersecurity assessments. There's no catch, just thirty minutes of pure, no-nonsense evaluation of your tech setup. Couldn’t hurt to know where...

Continue Reading
XPLR Infrastructure Posts Solid Q3 Results, Eyes Growth

Updated Category News Views 104

Third Quarter Results: Crunching the Numbers Every season brings new tidbits, and when XPLR Infrastructure, LP (NYSE: XIFR) dropped their third-quarter 2026 results, you bet I was ready with my magnifying glass. November 3rd was the day to circle on your calendars, as the folks over at Juno Beach sure had something to say. They’ve plastered the details across their...

Continue Reading
Mothers® Unveils New Wheel & Tire Care Products

Updated Category News Views 34

Revamping Auto Care: The New Products from Mothers® Diving headfirst into the glossy world of wheel and tire care is Mothers®, armed with two fresh products: Spray & Shine All Wheel Cleaner and Back-to-Black® Extreme Tire Shine. These aren’t just any off-the-shelf quick fixes—they’re born out of over half a century of relentless pursuit of vehicular perfection....

Continue Reading
CStone, Kimia Collaboration Targets Solid Tumor Survival

Updated Category News Views 74

Biotech Giants CStone and Kimia Unite Forces In the heart of China's biotechnology scene, the latest collaboration news to hit the wires is CStone Pharmaceuticals shaking hands with Kimia Therapeutics. Now, don't go tossing this aside as another run-of-the-mill partnership announcement. CStone's HKEX: 2616 ticker has got its eyes locked on an ambitious dance with Kimia,...

Continue Reading
EXPO 2027 Belgrade: Serbia's Tourism Game-Changer?

Updated Category News Views 15

An Unexpected Stage: Belgrade's Big Show Well, who's betting on Belgrade making waves in the global travel scene? EXPO 2027 is shaping up to do just that, and it’s taking the scenic route. Serbia, a country not always on the grand tourist itineraries, could finally hog the spotlight come 2027. Under the banner of 'Play for Humanity: Sport and Music for All,' they're...

Continue Reading
OSL Unveils Instant Redemption for USDGO Plus SP

Updated Category News Views 107

OSL's New Move: Instant Redemption on the Table Alright, let's chew over OSL's latest gambit—you know, those folks (HKEX: 863) who are knee-deep in the digital currency swamp. They've launched this "Instant Redemption" feature for these fancy real-world asset products, and USDGO Plus SP is right there at the forefront. Getting the Fine Print Straight Now, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Blue Shield of California Gains Praise for Health Equity Efforts

Updated Category News Views 173

Blue Shield of California's Commitment to Health Equity Blue Shield of California, a renowned nonprofit health plan, serves 6 million members across its state. Recently, it has garnered nationwide recognition for its exceptional dedication to health equity and its efforts to enhance access to culturally relevant care. The nonprofit health plan achieved a perfect score in...

Continue Reading
Onconetix and Ocuvex Conclude Merger Agreement: What's Next?

Updated Category News Views 139

Onconetix and Ocuvex Announce Merger Agreement Termination Two pioneering companies, Onconetix, Inc. (Nasdaq: ONCO) and Ocuvex Therapeutics, have chosen to part ways, terminating their merger agreement originally dated July 16, 2025. This decision comes after extensive dialogue and consideration, reflecting both companies' dedication to their missions and the stakeholders...

Continue Reading
FedEx Partners with Nimble to Enhance Supply Chain Efficiency

Updated Category News Views 101

FedEx Boosts Supply Chain with Investment in Nimble FedEx (NYSE: FDX) has made an exciting announcement regarding its investment in Nimble, a company that specializes in AI robotics and autonomous technologies. This strategic decision is aimed at enhancing the capabilities of FedEx's Fulfillment division, which focuses on supporting small and medium-sized businesses with...

Continue Reading
CNC Controller Market Forecast: $7.2 Billion by 2033

Updated Category News Views 121

Growth Projections for the CNC Controller Market The global CNC controller market is witnessing impressive growth, driven by several important factors, particularly the increasing automation in manufacturing. This need for efficiency and precision has stimulated the demand across multiple sectors, particularly the aerospace industry, ensuring CNC controllers are at the...

Continue Reading
Innovative Collaboration to Develop Keytruda Biosimilar by Alvotech

Updated Category News Views 212

Collaboration Between Alvotech and Dr. Reddy’s Laboratories In an exciting new partnership, Alvotech, a leading global biotech company known for its pioneering work in biosimilar medicines, has teamed up with Dr. Reddy’s Laboratories to co-develop a biosimilar candidate aimed at replicating Keytruda, whose generic name is pembrolizumab. This therapeutic is widely...

Continue Reading